$92.6 Million is the total value of Corriente Advisors, LLC's 11 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 300.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Buy | APTOSE BIOSCIENCES INC | $17,333,000 | +574.7% | 2,918,000 | +544.1% | 18.71% | +1255.8% | |
CUE | Buy | CUE BIOPHARMA INC | $11,636,000 | +157.2% | 820,000 | +187.7% | 12.56% | +416.9% |
New | GRAYSCALE BITCOIN ORD | $4,201,000 | – | 590,000 | +100.0% | 4.54% | – | |
PIRS | New | PIERIS PHARMACEUTICALS INC | $4,063,000 | – | 1,781,921 | +100.0% | 4.39% | – |
EPZM | New | EPIZYME INC | $3,567,000 | – | 230,000 | +100.0% | 3.85% | – |
SDGR | New | SCHRODINGER ORD | $2,587,000 | – | 60,000 | +100.0% | 2.79% | – |
SNSS | New | SUNESIS PHARMACEUTICALS INC | $1,254,000 | – | 3,021,692 | +100.0% | 1.35% | – |
TSLA | New | TESLA INC | $1,048,000 | – | 2,000 | +100.0% | 1.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-18
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CUE BIOPHARMA INC | 8 | Q3 2021 | 26.7% |
MAXAR TECHNOLOGIES INC | 7 | Q2 2021 | 41.3% |
REATA PHARMACEUTICALS INC | 6 | Q2 2021 | 29.6% |
REPLIMUNE GROUP INC | 5 | Q2 2021 | 12.1% |
APTOSE BIOSCIENCES INC | 5 | Q4 2020 | 18.7% |
CARDIFF ONCOLOGY INC | 5 | Q2 2021 | 9.5% |
DIAMEDICA THERAPEUTICS INC | 5 | Q2 2021 | 2.9% |
TFF PHARMACEUTICALS INC | 4 | Q3 2021 | 15.2% |
INVESCO QQQ TR | 3 | Q3 2022 | 94.7% |
LANTERN PHARMA INC | 3 | Q3 2021 | 13.5% |
View Corriente Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Cardiff Oncology, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
Cue Biopharma, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
TFF Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
CATABASIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
NAUTILUS, INC.Sold out | February 16, 2021 | 0 | 0.0% |
Maxar Technologies Inc. | November 26, 2019 | 2,920,750 | 4.9% |
CATABASIS PHARMACEUTICALS INC | February 23, 2018 | 1,692,899 | 7.3% |
NEUROLOGIX INC/DE | February 14, 2011 | 16,858,224 | 37.7% |
AMERICAN VANTAGE COMPANIESSold out | February 16, 2010 | 0 | 0.0% |
AspenBio Pharma, Inc.Sold out | February 16, 2010 | 0 | 0.0% |
View Corriente Advisors, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-09 |
13F-HR | 2023-05-10 |
13F-HR | 2023-02-15 |
13F-HR | 2022-11-15 |
13F-HR | 2022-08-16 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-15 |
SC 13G/A | 2022-02-14 |
View Corriente Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.